

THRU ONLINE FILING

August 10, 2022

BSE Ltd.
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 023
Scrip Code – 524494

National Stock Exchange India Limited,
Exchange Plaza, C-1, Block-G,
Bandra Kurla Complex, Bandra – (East).
Mumbai-400051.
Scrip Code : IPCALAB

Dear Sirs,

Re : Outcome of Board Meeting held on 10th August, 2022

1. Pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith our Standalone and Consolidated Unaudited Financial Results along with its limited review reports by the Company's Auditors for the 1st Quarter ended 30th June, 2022 of the financial year 2022-23, which was taken on record at the Meeting of the Board of Directors of the Company held today at Mumbai.

We are also enclosing herewith a press release issued by the Company in respect of its Q1 FY23 unaudited financial Results.


2. The Board noted the sad and sudden demise of Mr. Dev Parkash Yadava, Independent Director on 2nd August, 2022 and that he has ceased to be an Independent Director of the Company with effect from the said date.
3. The Board has re-constituted the Corporate Social Responsibility Committee of the Board with effect from 10th August, 2022 and the revised Committee will comprise of the following Board Members:

Corporate Social Responsibility Committee	
Mr. Kamal Kishore Seth	Independent Director
Mr. Premchand Godha	Chairman & Managing Director / CEO
Mr. A. K. Jain	Joint Managing Director/CFO
Mr. Prashant Godha	Executive Director

Kindly note that the Board meeting started at 11.15 a.m. and concluded at 1.10 p.m.

Thanking you

Yours faithfully
For Ipca Laboratories Limited



Harish P. Kamath
Corporate Counsel & Company Secretary

Encl: a/a

Ipca Laboratories Ltd.
www.ipca.com

Ipca Laboratories Limited

Regd. Office : 48, Kandivli Industrial Estate, Kandivli (W), Mumbai 400 067


CIN : L24239MH1949PLC007837

Tel:+91 22 6647 4444, E-mail : investors@ipca.com Website : www.ipca.com

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2022



(₹ Crores)

Sr. No.	Particulars	Quarter Ended			Year Ended
		June 30, 2022	March 31, 2022	June 30, 2021	March 31, 2022
		Unaudited	Audited*	Unaudited	Audited
I	Revenue from operations	1469.28	1168.45	1478.60	5399.36
II	Other Income	18.81	14.21	13.61	56.13
III	Total Income (I+II)	1488.09	1182.66	1492.21	5455.49
IV	Expenses				
	a) Cost of materials consumed	439.73	394.69	404.08	1600.98
	b) Purchases of stock-in-trade	60.92	91.31	52.14	282.90
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	15.91	(132.75)	41.97	(120.76)
	d) Employee benefits expense	297.67	272.27	280.64	1089.63
	e) Finance costs	6.79	3.21	1.26	7.21
	f) Depreciation and amortisation expense	53.41	52.39	49.96	204.10
	g) Other expenses	397.60	363.91	305.79	1303.07
	Total Expenses (IV)	1272.03	1045.03	1135.84	4367.13
V	Profit before exceptional items and tax (III-IV)	216.06	137.63	356.37	1088.36
VI	Exceptional items	-	-	-	-
VII	Profit before tax (V-VI)	216.06	137.63	356.37	1088.36
VIII	Tax Expense				
	-Current tax	59.45	30.90	62.50	197.20
	-Short / (Excess) provision of earlier years	-	0.08	-	0.08
	-Deferred tax liability / (asset)	12.79	(3.76)	9.15	20.14
IX	Profit for the period from continuing operations (VII-VIII)	143.82	110.41	284.72	870.94
X	Other Comprehensive Income				
	A (i) Items that will not be reclassified to profit or loss -				
	- Actuarial gain/(loss)	0.88	1.42	(0.37)	1.26
	- Remeasurement of Investment	-	0.15	-	0.15
	(ii) Income tax relating to items that will not be reclassified to profit or loss	(0.24)	(0.28)	0.06	(0.25)
	B (i) Items that will be reclassified to profit or loss				
	- Exchange difference in translating the financial statement of foreign operation	(0.31)	0.07	(0.13)	(0.54)
	- Gain/(loss) on cash flow hedge	-	-	0.23	0.54
	(ii) Income tax relating to items that will be reclassified to profit or loss	0.09	(0.01)	(0.02)	-
	Other Comprehensive Income / (Loss) for the period net of tax (X)	0.42	1.35	(0.23)	1.16
XI	Total Comprehensive income for the period (IX+X)	144.24	111.76	284.49	872.10
XII	Paid-up equity share capital (Face value of ₹ 1/- each)	25.37	25.37	25.37	25.37
XIII	Other Equity	-	-	-	5497.97
XIV	Net Worth	-	-	-	5523.34
XV	Earnings per share (of ₹ 1/- each) (Not annualised):				
	Basic (₹)	5.67	4.35	11.22	34.33
	Diluted (₹)	5.67	4.35	11.22	34.33



Notes:

- 1 The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on August 10, 2022. The Statutory Auditors have carried out the limited review of the results.
- 2 The Government of India has issued the Taxation Laws (Amendment) Act, 2019, which provides domestic companies an option to pay corporate tax at reduced rates effective April 1, 2019 subject to certain conditions. The Company has decided to opt for a lower tax regime under section 115BAA with effect from this financial year. In view of the same, outstanding MAT credit balance, which would not be available for set-off in future under the lower tax regime, has not been considered and as a result, carried forward deferred tax assets of Rs. 8.76 crores is charged off. Necessary impact on account of the above has been considered in computing provision for current tax and deferred tax.
- 3 The Board of Directors of the Company has approved a Scheme of Amalgamation whereby two wholly owned subsidiaries of the Company viz, M/s. Ramdev Chemical Pvt. Ltd. and M/s. Tonira Exports Pvt. Ltd. will get amalgamated with the Company with effect from 1st April, 2022. Such amalgamation is subject to receipt of requisite approvals. In view of the same, no effect of the same have been considered in the financial results.
- 4 *The figures for the quarter ended March 31, 2022 are the balancing figures between audited figures in respect of the full financial year 2021-22 and the published year to date unaudited figures upto December 31, 2021.
- 5 The Company has only one operating segment viz. 'Pharmaceuticals'.
- 6 Figures for the previous period have been regrouped / re-classified to conform to the figures of the current period.



By Order of the Board
For Ipca Laboratories Limited



Premchand Godha
Chairman & Managing Director
(DIN 00012691)

Place : Mumbai,
Date : August 10, 2022

G. M. KAPADIA & CO.

(REGISTERED)

CHARTERED ACCOUNTANTS

1007, RAHEJA CHAMBERS, 213, NARIMAN POINT, MUMBAI 400 021. INDIA

PHONE : (91-22) 6611 6611 FAX : (91-22) 6611 6600

Independent Auditor's Review Report on unaudited standalone quarterly financial results of Ipcalaboratories Limited pursuant to the Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

To,
The Board of Directors
Ipcalaboratories Limited
Mumbai

1. We have reviewed the accompanying statement of unaudited standalone financial results ("the Statement") of Ipcalaboratories Limited ("the Company") for the quarter ended June 30, 2022, being submitted by the Company pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 'Interim Financial Reporting' ("Ind AS 34") prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards of Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and



G. M. KAPADIA & CO.

other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For G. M. KAPADIA & Co.
Chartered Accountants
Firm Registration No.104767W



Place: Mumbai
Dated: August 10, 2022

A handwritten signature in black ink, appearing to read "Atul Shah".

Atul Shah
Partner

Membership No.039569
UDIN: 22039569AOSAXE1550

Ipca Laboratories Limited

Regd. Office : 48, Kandivli Industrial Estate, Kandivli (W), Mumbai 400 067

CIN : L24239MH1949PLC007837


Tel: +91 22 6847 4444, E-mail : investors@ipca.com Website : www.ipca.com



STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2022

(₹ Crores)

Sr. No.	Particulars	Quarter Ended			Year Ended
		June 30, 2022	March 31, 2022	June 30, 2021	March 31, 2022
		Unaudited	Audited*	Unaudited	Audited
I	Revenue from operations	1585.74	1289.10	1585.79	5829.79
II	Other Income	22.11	14.54	21.02	86.57
III	Total Income (I+II)	1607.85	1303.64	1586.81	5896.36
IV	Expenses :				
	a) Cost of materials consumed	453.88	411.51	413.23	1664.20
	b) Purchases of stock-in-trade	113.15	142.46	96.62	480.30
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	11.70	(127.76)	35.85	(129.65)
	d) Employee benefits expense	322.72	297.74	299.60	1177.39
	e) Finance costs	6.94	3.38	1.82	7.69
	f) Depreciation and amortisation expense	61.71	60.94	55.87	232.42
	g) Other expenses	415.06	345.82	303.95	1328.28
	Total Expenses (IV)	1385.16	1134.09	1206.94	4760.64
V	Profit from ordinary activity before share of profit / (loss) of associates & joint venture, exceptional items & tax (III - IV)	222.69	169.55	379.87	1135.72
VI	Exceptional items	-	-	-	-
VII	Profit before tax (V - VI)	222.69	169.55	379.87	1135.72
VIII	Tax Expense				
	-Current tax	62.36	32.06	64.48	207.01
	-Short / (Excess) provision of earlier years	-	0.50	-	0.50
	-Deferred tax liability / (asset)	11.90	(3.80)	6.29	17.26
IX	Profit for the period from continuing operations before share of profit / (loss) of associates & joint venture (VII-VIII)	148.43	140.79	309.10	910.95
X	Add Share of Profit / (less loss) of associates & joint venture (net of tax) accounted by using the equity method	(3.19)	(8.81)	(2.43)	(21.16)
XI	Profit for the period from continuing operations before non - controlling interest (IX + X)	145.24	131.98	306.67	889.79
XII	Less profit / (add loss) attributable to non-controlling interest.	2.18	1.75	0.01	5.71
XIII	Profit for the period attributable to owners of the Company (XI - XII)	143.06	130.23	306.66	884.08
XIV	Other Comprehensive Income				
	A. (i) Items that will not be reclassified to profit or loss -				
	-Actuarial gain/(loss)	0.88	1.38	(0.37)	1.22
	-Fair Value change through Other comprehensive income	-	0.15	-	0.15
	(ii) Income tax relating to items that will not be reclassified to profit or loss	(0.24)	(0.27)	0.06	(0.24)
	B. (i) Items that will be reclassified to profit or loss				
	-Exchange difference in translating the financial statement of foreign operation	1.14	0.29	3.15	1.40
	-Gain/(loss) on cash flow hedge	-	-	0.23	0.54
	(ii) Income tax relating to items that will be reclassified to profit or loss	0.09	(0.01)	(0.02)	-
	C. Share of OCI from investment in associates	(0.01)	(0.04)	-	(0.07)
	Other Comprehensive Income / (Loss) for the period, net of tax	1.86	1.50	3.05	3.00
XV	Total Comprehensive Income for the period (XI + XIV)	147.10	133.48	309.72	892.79
	Other Comprehensive Income for the period attributable to :				
	Owners of the parent	1.86	1.52	2.97	2.95
	Non-controlling interest - profit / (loss)	-	(0.02)	0.08	0.05
		1.86	1.50	3.05	3.00
	Total Comprehensive Income for the period attributable to :				
	Owners of the parent	144.92	131.75	309.63	887.03
	Non-controlling interest - profit / (loss)	2.18	1.73	0.09	5.78
		147.10	133.48	309.72	892.79
XVI	Paid-up equity share capital (Face value of ₹ 1/- each)	25.37	25.37	25.37	25.37
XVII	Other Equity	-	-	-	5466.60
XVIII	Net Worth	-	-	-	5491.97
XIX	Earning per equity share (of ₹ 1/- each) (Not annualised):				
	Basic (₹)	5.64	5.13	12.09	34.85
	Diluted (₹)	5.64	5.13	12.09	34.85





Notes:

- 1 The above consolidated financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on August 10, 2022. The Statutory Auditors have carried out the limited review of the results.
- 2 The Government of India has issued the Taxation Laws (Amendment) Act, 2019, which provides domestic companies an option to pay corporate tax at reduced rates effective April 1, 2019 subject to certain conditions. The Company has decided to opt for a lower tax regime under section 115BAA with effect from this financial year. In view of the same, outstanding MAT credit balance, which would not be available for set-off in future under the lower tax regime, has not been considered and as a result, carried forward deferred tax assets of Rs. 8.76 crores is charged off. Necessary impact on account of the above has been considered in computing provision for current tax and deferred tax.
- 3 *The figures for the quarter ended March 31, 2022 are the balancing figures between audited figures in respect of the full financial year 2021-22 and the published year to date unaudited figures upto December 31, 2021.
- 4 In accordance with Ind AS-108 "Operating Segments", the operations of the Group are categorised in one segment viz Pharmaceuticals. The geographic information of the Group's revenues by the Company's country of domicile and other countries is tabulated hereunder:

PARTICULARS	(₹ Crores)					
	India		Outside India		Total	
	June'22	June'21	June'22	June'21	June'22	June'21
Segment Revenue	808.33	724.60	777.41	841.19	1585.74	1565.79
% of Total Segment Revenue	50.97%	46.28%	49.03%	53.72%	100.00%	100.00%

- 5 Figures for the previous periods have been regrouped / re-classified to conform to the figures of the current period.

SIGNED FOR IDENTIFICATION
BY

G. M. KAPADIA & CO.
MUMBAI.



By Order of the Board
For Ipca Laboratories Limited



Premchand Godha
Chairman & Managing Director
(DIN 00012691)

Place : Mumbai,
Date : August 10, 2022

G. M. KAPADIA & CO.

(REGISTERED)

CHARTERED ACCOUNTANTS

1007, RAHEJA CHAMBERS, 213, NARIMAN POINT, MUMBAI 400 021. INDIA

PHONE : (91-22) 6611 6611 FAX : (91-22) 6611 6600

Independent Auditor's Review Report on unaudited consolidated quarterly financial results of Ipcalaboratories Limited pursuant to the Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

To,
The Board of Directors
Ipcalaboratories Limited
Mumbai

1. We have reviewed the accompanying statement of unaudited consolidated financial results of Ipcalaboratories Limited ("the Parent") and its subsidiaries, (the Parent and its subsidiaries together referred to as the Group) and its share of the net profit / (loss) after tax and total comprehensive income / (loss) of its joint venture and associates for the quarter ended June 30, 2022 ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations, to the extent applicable.



5. The Statement includes unaudited standalone financial result / consolidated financial results wherever applicable, of the following entities:

Sr. No.	Name of the Entities
	Subsidiaries
1	Ipca Pharma Nigeria Limited, Nigeria
2	Ipca Pharmaceuticals Limited, SA. De CV, Mexico
3	Ipca Laboratories (U.K.) Limited, UK
4	Ipca Pharmaceuticals Inc. USA
5	Ipca Pharma (Australia) Pty Limited, Australia
6	Tonira Exports Limited, India
7	Ramdev Chemicals Private Limited, India
8	Trophic Wellness Private Limited, India
	Step down Subsidiaries
9	Onyx Scientific Limited, UK
10	Ipca Pharma (NZ) Pty Limited, New Zealand
11	Pisgah Labs Inc., USA
12	Bayshore Pharmaceuticals LLC, USA
	Joint Venture
13	Avik Pharmaceuticals Limited, India
	Associates
14	Krebs Biochemicals Industries Limited, India (reviewed results)
15	Lyka Labs Limited*(reviewed results)

* Consolidated Financial Statements

6. Based on our review conducted and procedures performed as stated in paragraph 3 and 4 above and based on the consideration of the review report of the other auditor and management certified financials referred to in paragraph 7 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
7. (i) The Statement includes the standalone financial results of twelve subsidiaries (including nine foreign subsidiaries) which have not been reviewed by their auditors or by us, whose unaudited standalone financial results reflect total revenues of Rs.125.63 crores, total net profit after tax of Rs.3.78 crores, total comprehensive income of Rs.12.08 crores, for the quarter ended June 30, 2022 as considered in statement. The Statement also includes the Group's share of net profit after tax of Rs.0.69 crores, total comprehensive income of Rs.0.69 crores for the quarter ended June 30, 2022 as considered in the Statement, in respect of one joint venture, based on their unaudited standalone financial



results which have not been reviewed by their auditor or by us. These financial results are certified by the management. Our conclusion on the Statement is not modified in respect of the above matters; and

(ii) We did not review the standalone financial result of one associate and consolidated financial result of one associate included in the Statement, in which the aggregate Group's share of net loss after tax is Rs. 3.88 crores, total comprehensive loss of Rs. 3.89 crores, for the quarter ended June 30, 2022, as considered in the Statement. The unaudited standalone/consolidated financial results of these associates have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of this associates, are based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above. Our conclusion on the Statement is not modified in respect of the above matters.

For G. M. KAPADIA & Co.

Chartered Accountants

Firm Registration No.104767W



A handwritten signature in black ink, appearing to read "Atul Shah".

Atul Shah

Partner

Membership No.039569

UDIN: 22039569AOSBTA4666

Place: Mumbai

Dated: August 10, 2022

PRESS RELEASE


Ipca Laboratories Q1 FY23 Unaudited Financial Results

Mumbai, August 10, 2022: Ipca Laboratories Limited today announced its unaudited financial results for the first quarter ended 30th June, 2022 of the financial year 2022-23.

Key Financials of Q1 FY23

- Standalone Net Total Income @ Rs.1488.09 crores in Q1 FY23 as against Rs. 1492.21 crores in Q1 FY22.
- Consolidated Net Total Income @ Rs. 1607.85 crores in Q1 FY23 as against Rs. 1586.81 crores in Q1 FY22.
- Exports Income @ Rs. 687.59 crores in Q1 FY23 as against Rs. 766.27 crores in Q1 FY22.
- Standalone EBIDTA margin (before forex (gain)/loss) @ 19.52% in Q1 FY23 as against 27.10% in Q1 FY22.
- Consolidated EBIDTA margin @ 19% in Q1 FY23 as against 27.36% in Q1 FY22.
- Standalone Net Profit down 49% at Rs. 143.82 crores.
- Consolidated Net Profit down 53% at Rs. 143.06 crores.

Standalone Q1 FY23 at a glance			(Rs. Crores)
Particulars	Q1 FY23	Q1 FY22	Growth
Net Total Income	1488.09	1492.21	-
Export Income	687.59	766.27	-10%
EBITDA before forex (gain)/loss	290.51	404.37	-28%
Forex (gain) / loss	14.25	(3.22)	-
Finance Cost	6.79	1.26	439%
Depreciation and Amortisation	53.41	49.96	7%
Tax Expense	72.24	71.65	1%
Net Profit after tax	143.82	284.72	-49%
Earnings per share of Re. 1/- each (Rs.)	5.67	11.22	-49%




Ipca Laboratories Ltd.
www.ipca.com

Consolidated Q1 FY23 at a glance			(Rs. Crores)
Particulars	Q1 FY23	Q1 FY22	Growth
Consolidated Net Total Income	1607.85	1586.81	1%
Consolidated EBITDA before forex (gain)/loss	305.57	434.10	-30%
Forex (gain) / loss	14.23	(3.46)	-
Finance Cost	6.94	1.82	281%
Depreciation and Amortisation	61.71	55.87	10%
Tax Expense	74.26	70.77	5%
Profit for the period including share of non – controlling interest but before share of profit / (loss) of associates & joint venture	148.43	309.10	-52%
Add share of profit / (less loss) of associates & joint venture	(3.19)	(2.43)	-
Less profit / (add loss) attributable to non – controlling interest	2.18	0.01	-
Consolidated Net Profit after tax	143.06	306.66	53%
Consolidated Earnings per share of Re. 1/- each (Rs.)	5.64	12.09	53%

Q1 FY23 Revenue break-up			(Rs. Crores)
Particulars	Q1 FY23	Q1 FY22	Growth
Formulations			
Domestic	684.80	612.97	12%
Exports			
Branded	92.88	108.55	-14%
Institutional	96.99	116.48	-17%
Generics	211.94	216.77	-2%
Total Formulations	1086.61	1054.77	3%
APIs			
Domestic	89.27	89.95	-1%
Exports	285.78	324.47	-12%
Total APIs	375.05	414.42	-10%
Other Operating Income	7.62	9.41	-19%
Standalone Revenue from Operations	1469.28	1478.60	-1%
Revenue from Operations – Subsidiaries	116.46	87.19	34%
Consolidated Revenue from Operations	1585.74	1565.79	1%
Other Income	22.11	21.02	5%
Consolidated Net Total Income	1607.85	1586.81	1%

About Ipca Laboratories:

Ipca is a fully integrated pharmaceutical company with a strong thrust on exports. Ipca is vertically integrated and produces Finished Dosage Forms (FDFs) and Active Pharmaceutical Ingredients (APIs).


 Premchand Godha
 Chairman & Managing Director

Contact Information:

Harish P. Kamath, Corporate Counsel & Company Secretary at harish.kamath@ipca.com or on +91-22-6210 6050 www.ipca.com

Ipca Laboratories Ltd.

125, Kandivli Industrial Estate, CTS No. 328, Kandivli (West), Mumbai 400 067 (Maharashtra), India | T: +91 22 6210 5000 F: +91 22 6210 5005

Regd. Office: 48, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067 (Maharashtra), India | T: +91 22 6647 4444

E: ipca@ipca.com CIN: L24239MH1949PLC007837

